Enzomenib
Phase 2Small molecule
Sumitomo Pharma America, Inc.Enzomenib is one of 28 small molecule programs targeting Acute Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Acute Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Venclexta
AbbViePhase 2
Fludara
SanofiPhase 2
Blincyto
AmgenPhase 2
Xospata
AstellasPhase 2
Vitrakvi
BayerPhase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enzomenib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details